Rigger Courtney J Andersen shares lifetime experience of natural & synthetic ropes, & Nigel Sharp gives a guide for products ...

Tenax Therapeutics said it will extend its Phase 3 clinical development of an oral form of levosimendan for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Tenax ...

In a report released today, Jonathan Aschoff from Roth MKM maintained a Buy rating on Tenax Therapeutics (TENX – Research Report), with a price target of $30.00. See what stocks are receiving ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Tenax™ IMS65 E23 36K 的拉伸强度为 5800 MPa，拉伸模量为 280 GPa，其加工性能和材料特性与现有成本较高的中模量碳纤维相当，因此该产品将成为未来工业 ...

(RTTNews) - Tenax Therapeutics, Inc. (TENX) announced an expansion of its Phase 3 LEVEL program for TNX-103 or oral levosimendan, a novel treatment for pulmonary hypertension with heart failure ...